Fig. 5: Exploratory 3-year overall survival for patients with unresectable stage III NSCLC who responded to prior chemoradiotherapy, receiving durvalumab or placebo in the PACIFIC clinical trial. | British Journal of Cancer

Fig. 5: Exploratory 3-year overall survival for patients with unresectable stage III NSCLC who responded to prior chemoradiotherapy, receiving durvalumab or placebo in the PACIFIC clinical trial.

From: Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Fig. 5

Shown are Kaplan–Meier curves for post hoc, exploratory 3-year OS, defined according to the RECIST v1.1, and assessed by blinded-independent central review. Tick marks indicate censored observations, and vertical dotted lines indicate the times of landmark OS analyses. The intention-to-treat population included all patients who underwent randomisation. Data cut-off for 3-year OS was January 31, 2019, and median follow-up was 33.3 months. Adapted from Gray et al.34 Copyright (2019), with permission from Elsevier.

Back to article page